MOTS-c is an investigational mitochondrial-derived peptide, not an FDA-approved medication for humans. It is often sold online as “research only,” but human safety and efficacy data remain very limited. Chia does not offer MOTS-c; patients interested in metabolic or longevity care should use a licensed clinician-reviewed pathway instead of self-sourcing peptides.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you buy MOTS-c peptide legally and safely?
You may see MOTS-c peptide for sale online, but buying it is not the same as getting a lawful, quality-controlled medication. MOTS-c is not FDA-approved for human use, and online listings often avoid medical claims by labeling the vial “research use only” 5.
Why many online MOTS-c products are labeled “research use only”
“Research use only” usually means a product is being sold for laboratory research, not for a person to use. That label does not tell you that the product is safe, sterile, correctly dosed, or appropriate for your health goals. USADA warns that MOTS-c is often found on websites with “for research purposes only” labels and is not approved by FDA for use in humans 5.
Why availability online does not prove safety, quality, or legality
A website can claim purity, testing, fast shipping, or “USA lab tested” status without giving you the same safeguards as a licensed clinical pathway. For injectable products, the key safety questions include sterility, identity, potency, storage, contamination risk, and whether a licensed clinician has reviewed your medical history. The FDA has warned broadly that unapproved drugs have not been reviewed for safety, effectiveness, or quality before marketing 13.
What to do before using any investigational peptide
If you are considering an investigational peptide, bring the exact product, label, website, and your goals to a licensed clinician. This is especially important if you have diabetes, heart disease, kidney disease, cancer history, immune disease, take prescription drugs, or compete in tested sport. Do not rely on a research-vendor protocol as medical care.
What is MOTS-c?
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. It is a mitochondrial-derived peptide, or MDP, meaning it is encoded by mitochondrial DNA rather than the nuclear DNA that encodes most human proteins 1.
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c
Mitochondria are the cell structures that help convert food energy into usable cellular energy. MOTS-c is unusual because its coding sequence sits within the mitochondrial 12S rRNA region. The original human and mouse work described MOTS-c as a 16-amino-acid peptide that can act as a signal between mitochondria and the rest of the cell 1.
How mitochondrial-derived peptides differ from standard peptide drugs
Many peptide drugs are designed to mimic a hormone or receptor signal. MOTS-c belongs to a newer research category: mitochondrial-derived peptides. Reviews describe MDPs, including MOTS-c and humanin, as small peptides that may help cells respond to metabolic stress, but this biology is still being worked out 2.
Why MOTS-c is discussed in metabolism, exercise, and longevity research
Researchers discuss MOTS-c because early studies link it to glucose metabolism, skeletal muscle signaling, AMP-activated protein kinase, or AMPK, and exercise-related mitochondrial signaling. In human volunteers, one study found that exercise increased circulating MOTS-c, while mouse experiments suggested effects on physical performance pathways 7. These findings are interesting, but they do not prove MOTS-c improves weight, diabetes, performance, or lifespan in people.
What does the research actually show?
MOTS-c research is strongest at the mechanism stage, not the patient-outcome stage. Most findings come from cells, animals, and early human observational work; that is useful science, but it is not the same as proving a medication works in people.
Cell and animal findings: metabolic signaling, glucose handling, and exercise-related pathways
In the 2015 Cell Metabolism study that named MOTS-c, Lee and colleagues reported that MOTS-c influenced metabolic homeostasis in mice and acted through the folate-AICAR-AMPK signaling pathway 1. Later reviews describe possible links with AMPK, mTORC1, insulin signaling, skeletal muscle metabolism, and age-related stress responses 2.
Side effects and safety limits matter here. Cell and mouse findings cannot tell us the right human dose, long-term safety, immune risk, heart risk, cancer risk, or whether benefits outweigh harms for a person. That is why preclinical MOTS-c findings should not be treated as proven human benefits.
Human observational findings: associations with age, BMI, fasting insulin, and HbA1c
Human observational studies have reported links between mitochondrial-derived peptide measures and metabolic markers such as age, body mass index, fasting insulin, and HbA1c 3. This kind of study can find patterns, but it cannot prove that giving MOTS-c improves insulin sensitivity, glucose, weight, or diabetes outcomes.
Human trials: what is registered and what remains unknown
A ClinicalTrials.gov record lists a study of MOTS-c for improving insulin sensitivity, which shows that human research is underway 4. A trial registry is not proof of safety or effectiveness. Until completed trial results are published and reviewed, the honest answer is that human clinical benefit remains unknown.
Why animal or biomarker findings should not be treated as proven human benefits
Longevity science often starts with cells, animals, or biomarkers. Those studies can help explain a pathway, but they cannot prove that a peptide helps people live longer. Current reviews discuss MOTS-c as promising research in aging and metabolic disease, while still describing the need for more clinical evidence 2. Individual results, if studied in future trials, may vary.
Is MOTS-c approved for weight loss, diabetes, or longevity?
MOTS-c is not FDA-approved for weight loss, diabetes, insulin resistance, performance, anti-aging, or longevity. It should not be treated as an established obesity or diabetes medication 5.
FDA approval status for human use
FDA approval means the agency has reviewed a drug’s data for a specific use, dose, population, manufacturing process, and labeling. MOTS-c does not have that status for any human indication. USADA’s patient-facing summary states that MOTS-c is not approved by FDA for use in humans 5.
Why MOTS-c is not an established obesity or diabetes treatment
For obesity and type 2 diabetes, clinicians need human outcomes: weight change, HbA1c, hypoglycemia risk, cardiovascular events, side effects, contraindications, and long-term safety. MOTS-c does not yet have published human outcome evidence comparable to approved metabolic medicines. That is why we frame it as investigational, not as a substitute for evidence-based care.
Why there is no proven human longevity outcome
MOTS-c is discussed in aging research because mitochondria, AMPK, and metabolic stress responses are tied to aging biology. But no study has shown that MOTS-c extends human lifespan. Reviews describe possible mechanisms and future therapeutic interest, not a proven longevity outcome 2.
What are the risks of buying MOTS-c online?
The main risks are not just “will it work?” They are unknown human dosing, uncertain long-term safety, product-quality problems, contamination risk, and anti-doping consequences for athletes.
Unknown human dosing and long-term safety
Because MOTS-c is not an FDA-approved medication, there is no FDA-reviewed human prescribing label, dose schedule, contraindication list, or long-term safety database. A registered study may help answer some questions in the future, but it does not make self-directed use safe now 4.
Quality-control concerns with research-only products
Research-only peptide products may not be made under the same standards used for prescription drugs. Risks include wrong identity, wrong strength, impurities, bacterial contamination, endotoxin contamination, poor storage, and unsafe handling. For an injected substance, those risks can be serious.
Reported adverse effects and why they are hard to interpret
USADA reports that people using MOTS-c products have described palpitations, injection-site irritation, insomnia, immune reactions, and fever 5. These reports are hard to interpret because products, purity, dose, route, and other substances may differ. Still, they are a clear reason not to treat online MOTS-c as low risk.
Special caution for competitive athletes
For tested athletes, MOTS-c creates anti-doping risk. The World Anti-Doping Agency Prohibited List includes mitochondrial open reading frame of the 12S rRNA-c under S4 metabolic modulators, AMPK activators, prohibited at all times 6. Athletes should work with qualified sport-medicine and anti-doping experts before using any peptide or supplement.
Does Chia sell MOTS-c?
Chia does not offer MOTS-c. We do not prescribe, sell, compound, or ship MOTS-c. This article is education-only because MOTS-c is not in our current public treatment catalog.
How Chia handles available treatments
For treatments Chia does offer, care starts with a short online health questionnaire. A licensed US provider reviews your health history and prescribes only when clinically appropriate. A prescription is never guaranteed, and dosing is provider-guided and adjusted over time.
Compounded medications at Chia
When Chia offers a compounded treatment, it is compounded in the US by a state-licensed 503A compounding pharmacy and shipped to the patient’s door. Compounded medications are not FDA-approved. Patients can message their care team through the patient portal between visits.
When metabolic care may involve established GLP-1 options instead of investigational peptides
If your goal is weight-management care, our providers may discuss treatments that are actually in Chia’s catalog, such as semaglutide injection or tirzepatide tablets and injections, when clinically appropriate. Semaglutide is the INN for a GLP-1 receptor agonist used in FDA-approved brand medications such as Wegovy and Ozempic; tirzepatide is the INN for a dual GIP/GLP-1 receptor agonist used in FDA-approved brand medications such as Zepbound and Mounjaro. Chia offers compounded semaglutide via 503A pharmacy as injections, and compounded tirzepatide via 503A pharmacy as tablets and injections; compounded formulations are not FDA-approved and do not have FDA-evaluated outcomes data.
For longevity-focused goals, Chia’s current catalog includes options such as NAD+ injection or nasal spray, Sermorelin injection, nasal spray, or tablets, and protocols like Foundation Longevity, which combines Sermorelin Injection, NAD+ Injection, and Glutathione Injection. These are not MOTS-c alternatives in a one-to-one sense; they are different treatments with different evidence, risks, and eligibility requirements.
How does MOTS-c compare with clinician-reviewed metabolic options?
MOTS-c and GLP-1 medicines are very different categories. Comparison can help you understand the evidence gap, but it does not mean one is a direct substitute for the other.
| Option | What it is | Human evidence status | Key risks and limits | Chia availability |
|---|---|---|---|---|
| MOTS-c | Investigational mitochondrial-derived peptide encoded in mitochondrial DNA | Mostly cell, animal, mechanistic, and observational research; registered human study is ongoing | Not FDA-approved for human use; unknown dosing and long-term safety; prohibited in sport | Not offered by Chia |
| Semaglutide | GLP-1 receptor agonist; active ingredient in FDA-approved brand drugs such as Wegovy and Ozempic; also compounded by licensed 503A pharmacies where appropriate | The active ingredient semaglutide has FDA-approved labels for specific indications in brand products; compounded formulations are not FDA-approved and have no FDA-evaluated outcomes data | Common GLP-1 risks include nausea, vomiting, diarrhea, constipation, gallbladder problems, pancreatitis warnings, and contraindications listed in FDA labeling | Chia offers compounded semaglutide injection; plans currently start at $249/mo |
| Tirzepatide | Dual GIP/GLP-1 receptor agonist; active ingredient in FDA-approved brand drugs such as Zepbound and Mounjaro; also compounded by licensed 503A pharmacies where appropriate | The active ingredient tirzepatide has FDA-approved labels for specific indications in brand products; compounded formulations are not FDA-approved and have no FDA-evaluated outcomes data | Common risks include nausea, diarrhea, vomiting, constipation, pancreatitis warnings, gallbladder problems, and contraindications listed in FDA labeling | Chia offers compounded tirzepatide tablets and injections; plans currently start at $249/mo for tablets and $299/mo for injections |
| NAD+, Sermorelin, Glutathione | Longevity-focused treatments with different mechanisms than MOTS-c | Evidence varies by compound, route, and goal; they should be discussed with a clinician rather than treated as universal anti-aging therapies | Eligibility, interactions, side effects, and goals need clinician review | Chia offers NAD+ injection and nasal spray, Sermorelin injection, nasal spray, and tablets, and Glutathione injection and nasal spray |
Semaglutide and tirzepatide have FDA-reviewed labels for specific brand products, including dose-escalation schedules and safety warnings. For example, Wegovy labeling describes semaglutide as a once-weekly injection titrated over time to a maintenance dose of 2.4 mg for chronic weight management in indicated patients 8. Zepbound labeling describes tirzepatide as a once-weekly injection with maintenance doses of 5 mg, 10 mg, or 15 mg for indicated patients 9. These label facts should not be read as dosing instructions for you.
The safety balance is also clearer for labeled GLP-1 medicines than for MOTS-c because FDA labels list studied adverse reactions and warnings. Semaglutide and tirzepatide can cause gastrointestinal side effects and carry warnings for pancreatitis, gallbladder disease, kidney injury related to dehydration, and thyroid C-cell tumor risk based on rodent findings 8, 9. A clinician review matters because risks differ by person.
What should you do if you are considering MOTS-c?
If you are considering MOTS-c, pause before buying. The safer next step is to review your goals, health history, medications, sport status, and the exact product source with a licensed clinician.
- 1Bring the product label, seller website, certificate of analysis if present, and your goals to a licensed clinician.
- 2Avoid using research-only peptides as self-directed treatment, especially injectable products.
- 3Ask about evidence-based options for weight, glucose, energy, sexual health, hormones, or longevity goals.
- 4If your goal fits a treatment Chia actually offers, you can start with our online eligibility quiz. A licensed provider reviews your information, and a prescription is not guaranteed.
- 5If an AI agent is helping you navigate care, Chia can also be reached through DoctorMCP at mcp.chia.health for treatments Chia actually offers.
At Chia, we would rather give you a clear “not offered” than blur the line between research chemicals and prescription care. For offered treatments, our focus is a licensed-provider evaluation, state-licensed 503A pharmacy fulfillment, provider-guided dosing, and home delivery when appropriate.
FAQ
No. MOTS-c is not FDA-approved for human use, weight loss, diabetes, performance, anti-aging, or longevity.
MOTS-c is investigational and not an FDA-approved medication for humans. Chia does not offer it, prescribe it, compound it, or ship it.
Online availability does not prove that a product is lawful, safe, sterile, or appropriate for human use. Many MOTS-c products are labeled “research use only,” which is not the same as a prescription medication pathway.
MOTS-c has been studied in metabolic pathways, but it is not an established weight-loss treatment. Human evidence is too limited to say it reliably helps people lose weight.
A human study record exists for MOTS-c and insulin sensitivity, but registered research is not the same as proven clinical benefit. Published human outcome data remain limited.
No. MOTS-c is a mitochondrial-derived peptide. GLP-1 medicines, such as semaglutide, work through GLP-1 receptor signaling. Tirzepatide works through both GIP and GLP-1 receptor signaling.
No. Chia does not offer MOTS-c. We only discuss it here for education because patients often see it online.
Chia offers compounded semaglutide injection and compounded tirzepatide tablets and injections, when clinically appropriate after licensed-provider review. Compounded medications are not FDA-approved, and prescriptions are never guaranteed.
References
- 1.Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015.
- 2.Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018.
- 3.Wang Y, Li H, Wang X, et al. The correlation between mitochondrial derived peptide levels and metabolic markers in humans. Diabetology & Metabolic Syndrome. 2024.
- 4.ClinicalTrials.gov. MOTS-c for Improving Insulin Sensitivity in Humans, NCT07505745. 2026.
- 5.United States Anti-Doping Agency. What is the MOTS-c peptide? USADA. 2026.
- 6.World Anti-Doping Agency. The 2026 Prohibited List: International Standard. WADA. 2026.
- 7.Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021.
- 8.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. FDA. 2024.
- 9.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. FDA. 2025.
- 10.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting materials for bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. FDA. 2026.
- 11.Drug Topics. FDA advisory committee recommends six of seven nominated peptides for the 503A Bulks List, including MOTS-c, BPC-157, TB-500, KPV, Semax, and Epitalon. Drug Topics. 2026.
- 12.Lee C, Kim KH, Cohen P. MOTS-c: A promising mitochondrial-derived peptide for therapeutic use. Frontiers in Endocrinology. 2023.
- 13.U.S. Food and Drug Administration. Unapproved Drugs: Drugs Marketed in the United States That Do Not Have Required FDA Approval. FDA. 2024.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
